The drug, VE202, showed promise in preclinical studies of autoimmune disease and may be useful to individuals with inflammatory bowel disorders. Specifically, the drug may help treat Crohn’s disease and ulcerative colitis, according to the report.
Despite Johnson & Johnson already selling its own biotech drugs for the two conditions, the company may develop Vedanta’s for additional uses under terms similar to the bowel disease licensing deal.
More articles on Johnson & Johnson:
Experimental Ebola vaccine by Johnson & Johnson begins trials
Medical device market to reach $361B this year
Stryker stock soars ahead of possible Smith & Nephew acquisition
